Equities Analysts Issue Forecasts for ENLV FY2025 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Equities research analysts at HC Wainwright reduced their FY2025 earnings per share estimates for shares of Enlivex Therapeutics in a research report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.59) per share for the year, down from their previous estimate of ($0.58). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share.

Separately, D. Boral Capital reissued a “buy” rating and set a $13.00 price objective on shares of Enlivex Therapeutics in a report on Monday, March 3rd.

Enlivex Therapeutics Stock Up 6.9 %

ENLV stock opened at $1.09 on Wednesday. The business has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.24. The stock has a market cap of $23.33 million, a price-to-earnings ratio of -1.11 and a beta of 1.11. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.59.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new stake in shares of Enlivex Therapeutics in the 4th quarter valued at about $26,000. Renaissance Technologies LLC increased its position in Enlivex Therapeutics by 112.6% during the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after buying an additional 84,203 shares during the period. Finally, Millennium Management LLC purchased a new stake in Enlivex Therapeutics in the fourth quarter valued at approximately $742,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.